Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ranok Closes $40 Million Series B for Protein Degredation Drugs

publication date: Aug 18, 2021

Ranok Therapeutics, a Hangzhou-Boston company, closed a $40 million Series B funding to advance its innovative targeted protein degradation technology. The company has developed a proprietary targeted protein degradation platform technology, CHAMP (Chaperone-mediated Protein Degradation). Chaperones are proteins that mark mis-folded proteins for degradation. The company plans to announce its lead program by the end of 2021. The B round was led by Lapam Capital and Shanghai Healthcare Capital, with Wu Capital, Zhongguancun Kaiyuan Capital also participating. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital